BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 219.86 Million USD | -59.14% |
| 2022 | 538.11 Million USD | 119.5% |
| 2021 | 245.15 Million USD | 15.07% |
| 2020 | 213.05 Million USD | -20.06% |
| 2019 | 266.52 Million USD | 40.52% |
| 2018 | 189.67 Million USD | 21.98% |
| 2017 | 155.49 Million USD | 799.64% |
| 2016 | 17.28 Million USD | 179.31% |
| 2015 | 6.18 Million USD | -54.22% |
| 2014 | 13.51 Million USD | -11.3% |
| 2013 | 15.23 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 220.66 Million USD | -6.91% |
| 2024 Q1 | 216.74 Million USD | 0.71% |
| 2023 Q4 | 219.86 Million USD | -3.55% |
| 2023 Q1 | 238.84 Million USD | -55.62% |
| 2023 Q3 | 227.96 Million USD | -2.26% |
| 2023 FY | 219.86 Million USD | -59.14% |
| 2023 Q2 | 233.24 Million USD | -2.34% |
| 2022 Q4 | 538.11 Million USD | 119.67% |
| 2022 Q3 | 244.96 Million USD | 7.85% |
| 2022 FY | 538.11 Million USD | 119.5% |
| 2022 Q2 | 227.12 Million USD | -5.99% |
| 2022 Q1 | 241.59 Million USD | -1.45% |
| 2021 Q3 | 238.51 Million USD | 4.14% |
| 2021 Q1 | 219.58 Million USD | 3.06% |
| 2021 Q4 | 245.15 Million USD | 2.78% |
| 2021 Q2 | 229.02 Million USD | 4.3% |
| 2021 FY | 245.15 Million USD | 15.07% |
| 2020 Q1 | 272.15 Million USD | 2.11% |
| 2020 Q2 | 322.82 Million USD | 18.61% |
| 2020 Q4 | 213.05 Million USD | 18.21% |
| 2020 FY | 213.05 Million USD | -20.06% |
| 2020 Q3 | 180.23 Million USD | -44.17% |
| 2019 Q4 | 266.52 Million USD | -2.67% |
| 2019 FY | 266.52 Million USD | 40.52% |
| 2019 Q2 | 257.47 Million USD | 2.09% |
| 2019 Q3 | 273.83 Million USD | 6.36% |
| 2019 Q1 | 252.19 Million USD | 32.97% |
| 2018 Q2 | 200.68 Million USD | 22.28% |
| 2018 FY | 189.67 Million USD | 21.98% |
| 2018 Q3 | 187.23 Million USD | -6.7% |
| 2018 Q4 | 189.67 Million USD | 1.3% |
| 2018 Q1 | 164.11 Million USD | 5.55% |
| 2017 FY | 155.49 Million USD | 799.64% |
| 2017 Q4 | 155.49 Million USD | 4.13% |
| 2017 Q3 | 149.32 Million USD | -2.23% |
| 2017 Q1 | 17.43 Million USD | 0.87% |
| 2017 Q2 | 152.72 Million USD | 776.04% |
| 2016 Q2 | 10.55 Million USD | 69.83% |
| 2016 Q4 | 17.28 Million USD | -4.14% |
| 2016 Q3 | 18.03 Million USD | 70.85% |
| 2016 Q1 | 6.21 Million USD | 0.42% |
| 2016 FY | 17.28 Million USD | 179.31% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q3 | 6.3 Million USD | 0.0% |
| 2015 Q4 | 6.18 Million USD | -1.87% |
| 2015 FY | 6.18 Million USD | -54.22% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q4 | 13.51 Million USD | 0.0% |
| 2014 FY | 13.51 Million USD | -11.3% |
| 2013 FY | 15.23 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 30.61 Million HKD | -618.244% |
| CK Life Sciences Int'l., (Holdings) Inc. | 4.27 Billion HKD | 94.854% |